Sarasota biotech company regains NYSE compliance

Oragenics is developing drug candidates for treating mild traumatic brain injury and concussion.
Oragenics is developing drug candidates for treating mild traumatic brain injury and concussion.
Courtesy image
  • Manatee-Sarasota
  • Share

A Sarasota biotech company has regained compliance with the New York Stock Exchange’s American listing standards. Oragenics Inc. (NYSE American: OGEN) is now positioned to focus exclusively on advancing its lead clinical program, according to an Oct. 21 statement.

 

Continue reading your article
with a Business Observer subscription.
What's included:
  • ✓ Unlimited digital access to BusinessObserverFL.com
  • ✓ E-Newspaper app, digital replica of print edition
  • ✓ Mailed print newspaper every Friday (optional)
  • ✓ Newsletter of daily business news
Subscribe

Already subscribed? Sign in.

Latest News

  • March 19, 2026
Hoffmann Family sets opening date for Naples boutique
  • March 19, 2026
Luxury Naples community sells $50M in homes in first two months of 2026
  • March 19, 2026
Water slides, bowling, go-karts and lots more coming to Lakewood Ranch
  • March 19, 2026
Downtown Sarasota apartment project would replace breakfast restaurant

Sponsored Content